Senescence bypass in mesenchymal stem cells: a potential pathogenesis and implications of pro-senescence therapy in sarcomas

References

• de Silva Meirelles L, Chagastelles PC, Nardi NB. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J. Cell Sci. 119, 2204–2213 (2006).
   PubMedGoogle Scholar
• Dominici M, Le Blanc K, Mueller I et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8, 315–317 (2006).
   PubMed Web of Science ®Google Scholar
• Garcia-Castro J, Trigueros C, Madrenas J et al. Mesenchymal stem cells and their use as cell replacement therapy and disease modeling tool. J. Cell Mol. Med. 12, 2552–2565 (2008).
   PubMed Web of Science ®Google Scholar
• Mackall CL, Meltzer PS, Helman LJ. Focus on sarcomas. Cancer Cell 2(3), 175–178 (2002).
   PubMed Web of Science ®Google Scholar
• Mohseny AB, Hogendoorn PC. Mesenchymal tumors: when stem cells go mad. Stem Cells 29, 397–403 (2011).
   PubMed Web of Science ®Google Scholar
• Helman LJ, Meltzer P. Mechanisms of sarcoma development. Nat. Rev. Cancer 3, 685–694 (2003).
   PubMed Web of Science ®Google Scholar
• Skubitz KM, D’Adamo DR. Sarcoma. Mayo Clin. Proc. 82, 1409–1432 (2007).
   PubMed Web of Science ®Google Scholar
• Tolar J, Nauta AJ, Osborn MJ et al. Sarcoma derived from cultured mesenchymal stem cells. Stem Cells 25, 371–379 (2007).
   PubMed Web of Science ®Google Scholar
• Rosland GV, Svendsen A, Torsvik A et al. Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Cancer Res. 69, 5331–5339 (2009).
   PubMed Web of Science ®Google Scholar
• Tirode F, Laud-Duval K, Prieur A et al. Mesenchymal stem cell features of Ewing tumors. Cancer Cell 11, 421–429 (2007).
   PubMed Web of Science ®Google Scholar
• Tang N, Song WX, Luo J et al. Osteosarcoma development and stem cell differentiation. Clin. Orthop. Relat. Res. 466, 2114–2130 (2008).
   PubMed Web of Science ®Google Scholar
• Rodriguez R, Rubio R, Masip M et al. Loss of p52 induces tumorigenesis in p21-deficient mesenchymal stem cell. Neoplasia 11, 397–407 (2009).
   PubMedGoogle Scholar
• Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp. Cell Res. 25, 614–636 (1965).
   Google Scholar
• Haley CR, Futcher AB, Greider CW. Telomeres shorten during aging of human fibroblasts. Nature 345, 458–460 (1990).
   PubMedGoogle Scholar
• Watson JD. Origin of concatemeric T7 DNA. Nat. Rev. Biol. 239, 197–201 (1972).
   Google Scholar
• D’Adda di Fagagna F. Living on a break: Cellular senescence as a DNA-damage response. Nat. Rev. Cancer 8, 512–522 (2008).
   PubMed Web of Science ®Google Scholar
• Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 120, 513–522 (2005).
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 100, 57–70 (2000).
   PubMed Web of Science ®Google Scholar
• Smith JR, Pereira-Smith OM. Replicative senescence: implications for in vivo aging and tumor suppression. Science 273(5271), 63–67 (1996).
   PubMed Web of Science ®Google Scholar
• Vergel M, Carnero A. Bypassing cellular senescence by genetic screening tools. Clin. Translat. Oncol. 12(6), 410–417 (2010).
   PubMedGoogle Scholar
• Rubio D, Garcia S, Paz MF et al. Molecular characterization of spontaneous mesenchymal stem cell transformation. PLoS ONE 3(2), e1398 (2008).
   Google Scholar
• D’Adda di Fagagna F, Reaper PM, Clay-Farrace L et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature 426, 194–198 (2003).
   PubMed Web of Science ®Google Scholar
• Kiyono T, Foster SA, Koop JI et al. Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 396, 84–88 (1998).
   PubMed Web of Science ®Google Scholar
• Piper SL, Wang M, Yamamoto A et al. Inducible immortality in hTERT-human mesenchymal stem cells. J. Orthop. Res. 30, 1879–1885 (2012).
   PubMedGoogle Scholar
• Chen Q, Fischer A, Reagan JD et al. Oxidative DNA damage and senescence of human diploid fibroblast cells. Proc. Natl. Acad. Sci. 92, 4337–4341 (1995).
   PubMed Web of Science ®Google Scholar
• Di Micco R, Fumagalli M, Cicalese A et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 444(7119), 638–642 (2006).
   PubMed Web of Science ®Google Scholar
• Mallete FA, Gaumont-Leclerc MF, Ferbeyre G. The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence. Genes Dev. 21(1), 43–48 (2007).
   PubMedGoogle Scholar
• Chen Z, Trotman LC, Shaffer D et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436, 725–730 (2005).
   PubMed Web of Science ®Google Scholar
• Zhang W, Ji W, Yang L et al. Comparison of global DNA methylation profiles in replicative versus premature senescence. Life Sci. 83, 475–480 (2008).
   PubMedGoogle Scholar
• Lee S, Park JR, Seo MS et al. Histone deacetylase inhibitors decrease proliferation potential and multilineage differentiation capability of human mesenchymal stem cells. Cell Prolif. 42(6), 711–720 (2009).
   PubMed Web of Science ®Google Scholar
• Coppe JP, Patil CK, Rodier F et al. Senescence-associated secretory phenotype reveal cell-nonautonomous functions of oncogenic RAS and p53 tumor suppressor. PLoS Biol. 6(12), 2853–2868 (2008).
   PubMed Web of Science ®Google Scholar
• Acosta JC, O’Leghlen A, Banito A et al. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 133(6), 1006–1018 (2008).
   PubMed Web of Science ®Google Scholar
• Zeng G, Millis AJ. Differential regulation of collagenase and stromelysin mRNA in late passage cultures of human fibroblasts. Exp. Cell Res. 222(1), 150–156 (1996).
   PubMed Web of Science ®Google Scholar
• Kuilman T, Michaloglou C, Vredeveld LC et al. Oncogene-induced senescence related by an interleukin-dependent inflammatory network. Cell 133(6), 1019–1031 (2008).
   PubMed Web of Science ®Google Scholar
• Orjalo AV, Bhaumik D, Gengler B et al. Cell surface-bound IL-1alpha is an upstream regulator of the senescence-associated IL-6/IL-8 cytokine network. Proc. Natl Acad. Sci. USA 106(40), 17031–17036 (2009).
   PubMed Web of Science ®Google Scholar
• Pan L, Chen S, Weng C et al. Stem cell aging is controlled both intrinsically and extrinsically in the Drosophila ovary. Cell Stem Cell 1(4), 458–469 (2007).
   Google Scholar
• Mayack SR, Shadrach JL, Kim FS, Wagners AJ. Systemic signal regulate ageing and rejuvenation of blood stem cell niches. Nature 463(7280), 495–500 (2010).
   PubMed Web of Science ®Google Scholar
• Feldser DM, Greider CW. Short telomeres limit tumor progression in vivo by inducing senescence. Cancer Cell 11, 461–469 (2007).
   PubMedGoogle Scholar
• Cosme-Blanco W, Shen M-F, Lazar AJF et al. Telomere dysfunction suppresses spontaneous tumorigenesis in vivo by initiating p53-dependent cellular senescence. EMBO Rep. 8, 497–503 (2007).
   PubMedGoogle Scholar
• Braig M, Lee S, Loddenkemper C et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 436, 660–665 (2005).
   PubMed Web of Science ®Google Scholar
• Sarkisian CJ, Keister BA, Stairs DB et al. Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat. Cell Biol. 9, 483–505 (2007).
   PubMedGoogle Scholar
• Ventura A, Kirsch DG, Mclaughlin ME et al. Restoration of p53 function leads to tumor regression in vivo. Nature 445, 661–665 (2007).
   PubMed Web of Science ®Google Scholar
• Xue W, Zender L, Miething C et al. Senescence and tumor clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445, 656–660 (2007).
   PubMed Web of Science ®Google Scholar
• Wu C-H, van Riggelen J, Yetil A et al. Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc. Natl Acad. Sci. USA 104, 13028–13033 (2007).
   PubMed Web of Science ®Google Scholar
• Li L, Clevers H. Coexistence of quiescent and active adult stem cells in mammals. Science 327, 542–545 (2010).
   PubMed Web of Science ®Google Scholar
• Brack AS, Rando TA. Intrinsic changes and extrinsic influences of myogenic stem cell function during aging. Stem Cell Rev. 3, 226–237 (2007).
   PubMed Web of Science ®Google Scholar
• Giangreco AM, Qin M, Pintar JE, Watt FM. Epidermal stem cells are retained in vivo throughout skin aging. Aging Cell 7, 250–259 (2008).
   PubMedGoogle Scholar
• Ben-Porath I, Weinberg RA. The signals and pathways activating cellular senescence. Int. J. Biochem. Cell Biol. 37, 961–976 (2005).
   PubMed Web of Science ®Google Scholar
• Koga H, Kasushik S, Cuervo AM. Protein homeostasis and aging: the importance of exquisite quality control. Ageing Res. Rev. 10, 205–215 (2011).
   PubMed Web of Science ®Google Scholar
• Brack AS, Conboy MJ, Roy S et al. Increased Wnt signaling during aging alters muscle stem cell fate and increases fibrosis. Science 317, 807–810 (2007).
   PubMed Web of Science ®Google Scholar
• Rittié L, Stoll SW, Kang S, Voorhees JJ, Fischer GJ. Hedgehog signaling maintains hair follicle stem cell phenotype in young and aged human skin. Aging Cell 8, 738–751 (2009).
   PubMed Web of Science ®Google Scholar
• Kudlow BA, Kennedy BK, Monnat RJ Jr. Werner and Hutchinson-Gilford progeria syndromes: mechanistic basis of human progeroid diseases. Nat. Rev. Mol. Cell Biol. 8, 394–404 (2007).
   PubMedGoogle Scholar
• Rossi DJ, Bryder D, Seita J et al. Deficiencies in DNA damage repair limit the function of haematopoietic stem cells with age. Nature 447, 725–729 (2007).
   PubMed Web of Science ®Google Scholar
• Sedivy JM, Banumathy G, Adams PD. Aging by epigenetics – a consequence of chromatin damage? Exp. Cell Res. 314, 1909–1917 (2008).
   PubMed Web of Science ®Google Scholar
• Rajawat YS, Hilioti Z, Bossis I. Aging: central role for autophagy and the lysosomal degradative system. Ageing Res. Rev. 8, 199–213 (2009).
   PubMed Web of Science ®Google Scholar
• Carlson ME, Conboy MJ, Hsu M et al. Relative roles of TGF-beta 1 and Wnt in the systemic regulation and aging of satellite cell response. Aging Cell 8, 676–689 (2009).
   PubMed Web of Science ®Google Scholar
• Conboy IM, Conboy MJ, Wagers AJ et al. Rejuvenation of aged progenitor cells by exposure to a young systemic environment. Nature 433, 760–764 (2005).
   PubMed Web of Science ®Google Scholar
• Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 284, 143–147 (1999).
   PubMed Web of Science ®Google Scholar
• Digirolamo CM, Stokes D, Colter D et al. Propagation and senescence of human marrow stromal cells in culture: a simple colony-forming assay identifies samples with the greatest potential to propagate and differentiate. Br. J. Haematol. 107, 275–281 (1999).
   PubMed Web of Science ®Google Scholar
• Dimri GP, Lee X, Basile G et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl Acad. Sci. USA 92, 9363–9367 (1995).
   PubMed Web of Science ®Google Scholar
• Bonab MM, Alimoghaddam K, Talebian F et al. Aging of mesenchymal stem cell in vitro. BMC Cell Biol. 7, 14–20 (2006).
   PubMed Web of Science ®Google Scholar
• Shibata KR, Aoyama T, Shima Y et al. Expression of p16INK4a gene is associated closely with senescence of human mesenchymal stem cells and is potentially silenced by DNA methylation during in vitro expansion. Stem Cells 25, 2371–2382 (2007).
   PubMed Web of Science ®Google Scholar
• Baxter MA, Wynn RF, Jowitt SN et al. Study of telomere length reveals rapid aging of human marrow stromal cells following in vitro expansion. Stem Cells 22, 675–682 (2004).
   PubMed Web of Science ®Google Scholar
• Rubin H. Promise and problems in relating cellular senescence in vitro to aging in vivo. Arch. Gerontol. Geniatr. 34, 275–286 (2002).
   PubMedGoogle Scholar
• Ross SE, Hemati N, Longo KA et al. Inhibition of adipogenesis by Wnt signaling. Science 289, 950–953 (2000).
   PubMed Web of Science ®Google Scholar
• Cheleuitte D, Mizuno S, Glowachi J. In vitro secretion of cytokines by human bone marrow: effects of age and estrogen status. J. Clin. Endocrinol. Metab. 83, 2043–2051 (1998).
   PubMedGoogle Scholar
• Moerman EJ, Teng K, Lipschitz DA, Lecka-Czernik B. Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-gamma2 transcription factor and TGF-beta/BMP signaling pathways. Aging Cell 3, 379–389 (2004).
   PubMed Web of Science ®Google Scholar
• Wagner W, Horn P, Castoldi M et al. Replicative senescence of mesenchymal stem cells: a continuous and organized process. PLoS ONE 3, e2213 (2008).
   PubMed Web of Science ®Google Scholar
• Noh HB, Ahn H-J, Lee W-J, Kwack K, Kwon YD. The molecular signature of in vitro senescence in human mesenchymal stem cells. Genes. Genomics. 32, 87–93 (2010).
   Google Scholar
• Clevers HH. Wnt/beta-catenin signaling in development and disease. Cell 127(3), 469–480 (2006).
   PubMed Web of Science ®Google Scholar
• Zhang D-Y, Wang H-J, Tan T-Z. Wnt/β-catenin signaling induces the aging of mesenchymal stem cells through the DNA damage response and the p53/p21 pathway. PLoS ONE 6, e21397 (2011).
   PubMed Web of Science ®Google Scholar
• Zhang D-A, Pan Y, Zhang C et al. Wnt/β-catenin signaling induces the aging of mesenchymal stem cells through promoting the ROS production. Mol. Cell Biochem. 374, 13–20 (2013).
   PubMed Web of Science ®Google Scholar
• Lee J-S, Lee M-O, Moon B-H et al. Senescent growth arrest in mesenchymal stem cells is bypassed by Wip1-mediated downregulation of intrinsic stress signaling pathways. Stem Cells 27, 1963–1975 (2009).
   PubMedGoogle Scholar
• Yuan H-F, Zhai C, Tan X-L et al. SIRT1 is required for long-term growth of human mesenchymal stem cells. J. Mol. Med. 90, 389–400 (2012).
   PubMedGoogle Scholar
• Alessio N, Bohn W, Rauchberger V et al. Silencing of RB1 but not RB2/P130 induces cellular senescence and impairs the differentiation potential of human mesenchymal stem cells. Cell Mol. Life Sci. 70(9), 1637–1651 (2013).
   PubMedGoogle Scholar
• Tsai C-C, Chen Y-J, Yew T-L et al. Hypoxia inhibits senescence and maintains mesenchymal stem cell properties through down-regulation of E2A-p21 by HIF-TWIST. Blood 117(2), 459–469 (2011).
   PubMed Web of Science ®Google Scholar
• Giorgio M, Trinei M, Migliaccio E et al. Hydrogen peroxide: a metabolic by-product or a common mediator of ageing signals? Nat. Rev. Mol. Cell Biol. 8, 722–728 (2007).
   PubMed Web of Science ®Google Scholar
• Brandl A, Meyer M, Bechmann V, Nerlich M, Angele P. Oxidative stress induces senescence in human mesenchymal stem cells. Exp. Cell Res. 317, 1541–1547 (2012).
   Google Scholar
• Heo J-Y, Jing K, Song K-S et al. Downregulation of APE1/Ref-1 is involved in the senescence of mesenchymal stem cells. Stem Cells 27, 1455–1462 (2009).
   PubMedGoogle Scholar
• Choi JW, Herr DR, Noguchi K et al. LPA receptors: subtypes and biological actions. Annu. Rev. Pharmacol. Toxicol. 50, 157–186 (2010).
   PubMed Web of Science ®Google Scholar
• Kanehira M, Kikuchi T, Ohkouchi S et al. Targeting lysophosphatidic acid signaling retards culture-associated senescence of human marrow stromal cells. PLoS ONE 7, e32185 (2012).
   Google Scholar
• Wagner W, Bork S, Horn P et al. Aging and replicative senescence have related effects on human stem and progenitor cells. PLoS ONE 4, e5846 (2009).
   PubMed Web of Science ®Google Scholar
• Geißler S, Textor M, Kühnisch J et al. Functional comparison of chronological and in vitro aging: differential role of the cytoskeleton and mitochondria in mesenchymal stromal cells. PLoS ONE 7, e52700 (2012).
   PubMed Web of Science ®Google Scholar
• Rubio D, Garcia-Castro J, Martin MC et al. Spontaneous human adult stem cell transformation. Cancer Res. 65, 3035–3039 (2005).
   PubMed Web of Science ®Google Scholar
• Li N, Yang R, Zhang W et al. Genetically transforming human mesenchymal stem cells to sarcomas: changes in cellular phenotype and multilineage differentiation potential. Cancer 115, 4795–4806 (2009).
   PubMed Web of Science ®Google Scholar
• Mohseny AB, Szuhai K, Romeo S et al. Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2. J. Pathol. 219, 294–305 (2009).
   PubMed Web of Science ®Google Scholar
• Wang Y, Huso DL, Harrington J et al. Outgrowth of a transformed cell population derived from normal human BM mesenchymal stem cell culture. Cytotherapy 7, 509–519 (2005).
   PubMed Web of Science ®Google Scholar
• Li H, Fan X, Kovi RC et al. Spontaneous expression of embryonic factors and p53 point mutations in aged mesenchymal stem cells: a model of age-related tumorigenesis in mice. Cancer Res. 67, 10889–10898 (2007).
   PubMed Web of Science ®Google Scholar
• Danielson LS, Menendez S, Attolini CS et al. A differentiation-based microRNA signature identifies leiomyosarcoma as a mesenchymal stem cell-related malignancy. Am. J. Pathol. 177, 908–917 (2010).
   PubMedGoogle Scholar
• Shimizu T, Ishikawa T, Sugihara E et al. c-MYC overexpression with loss of INK4a/Arf transforms bone marrow stromal cells into osteosarcoma accompanied by loss of adipogenesis. Oncogene 29, 5687–5699 (2010).
   PubMed Web of Science ®Google Scholar
• Lin PP, Pandey MK, Jin F et al. Targeted mutation of p53 and Rb in mesenchymal cells of the limb bud produces sarcomas in mice. Carcinogenesis 30, 1789–1795 (2009).
   PubMed Web of Science ®Google Scholar
• Casillero-Trejo Y, Eliazer S, Xiang L, Richradson JA, Ilaria RL Jr. Expression of the EWS/FLI-1 oncogene in murine primary bone-derived cells results in EWS/FLI-1-dependent Ewing sarcoma-like tumors. Cancer Res. 65, 8698–8705 (2005).
   PubMedGoogle Scholar
• Riggi N, Suvà ML, Suvà D et al. EWS-FLI-1 expression triggers a Ewing’s sarcoma initiation program in primary human mesenchymal stem cells. Cancer Res. 68, 2176–2185 (2008).
   PubMed Web of Science ®Google Scholar
• Rodriguez R, Rubio R, Guitierrez-Aranda I et al. Fus-Chop fusion protein expression coupled to p53 deficiency induces liposarcoma in mouse but not human adipose-derived mesenchymal stem/stromal cells. Stem Cells 29, 179–192 (2011).
   PubMedGoogle Scholar
• Riggi N, Cironi L, Provero P et al. Expression of the FUS-CHOP fusion protein in primary mesenchymal progenitor cells gives rise to a model of myxoid liposarcoma. Cancer Res. 66, 7016–7023 (2006).
   PubMed Web of Science ®Google Scholar
• Ren YX, Finckenstein FG, Abdueva DA et al. Mouse mesenchymal stem cells expressing PAX-FKHR form alveolar rhabdomyosarcomas by cooperating with secondary mutations. Cancer Res. 68, 6587–6597 (2008).
   PubMed Web of Science ®Google Scholar
• Hernando E, Charytonowicz E, Dudas ME et al. The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat. Med. 13, 748–753 (2007).
   PubMed Web of Science ®Google Scholar
• Cleton-Jansen AM, Anninga JK, Briaire-de Bruijn IH et al. Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumorigenic pathways. Br. J. Cancer 101, 1909–1918 (2009).
   PubMedGoogle Scholar
• Matushansky I, Hernando E, Socci ND et al. Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. J. Clin. Invest. 117, 3248–3257 (2007).
   PubMed Web of Science ®Google Scholar
• Honoki K, Fujii H, Tohma Y et al. Comparison of gene expression profiling in sarcomas and mesenchymal stem cells identifies tumorigenic pathways in chemically induced rat sarcoma model. ISRN Oncol. 2012, 909453 (2012).
   PubMedGoogle Scholar
• Noer A, Lindeman LC, Collas P. Histone h3 modifications associated with differentiation and long-term culture of mesenchymal adipose stem cells. Stem Cell Dev. 18(5), 725–736 (2009).
   PubMed Web of Science ®Google Scholar
• Carnero A, Hudson JD, Hannon GJ, Beach DH. Loss-of-function genetics in mammalian cells: the p53 tumor suppressor model. Nucleic Acids Res. 28(11), 2234–2241 (2000).
   PubMedGoogle Scholar
• Vassilev LT, Vu BT, Graves B et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844–848 (2004).
   PubMed Web of Science ®Google Scholar
• Wang B, Fang L, Zhao H, Xiang T, Wang D. MDM2 inhibitor Nutlin-3a suppresses proliferation and promotes apoptosis in osteosarcoma cells. Acta. Biochem. Biophys. Sin. 44(8), 685–691 (2012).
   Google Scholar
• Bykov VJ, Issaeva N, Shilov A et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat. Med. 8, 282–288 (2002).
   PubMed Web of Science ®Google Scholar
• Bykov VJ, Zache N, Stridh H et al. PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis. Oncogene 24(21), 3484–3491 (2005).
   PubMed Web of Science ®Google Scholar
• Johnsson P, Ackley A, Vidarsdottir L et al. A pseudogene long-encoding-RNA network regulates PTEN transcription and translation in human cells. Nat. Struct. Mol. Biol. 20(4), 440–446 (2013).
   PubMed Web of Science ®Google Scholar
• Carnero A. Targeting the cell cycle for cancer therapy. Br. J. Cancer 87(2), 129–133 (2002).
   PubMed Web of Science ®Google Scholar
• Lin H, Chen Z, Wang G et al. Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature 464, 374–379 (2010).
   PubMed Web of Science ®Google Scholar
• Chan CH, Gao Y, Moten A, Lin HK. Novel ARF/p53-independent senescence pathways in cancer repression. J. Mol. Med. (Berl.) 89(9), 857–867 (2011).
   PubMed Web of Science ®Google Scholar
• Mackintosh C, Garcia-Dominguex DJ, Ordóňez JL et al. WEE1 accumulation and deregulation of S-phase proteins mediate MLN4924 potent inhibitory effect on Ewing sarcoma cell. Oncogene 32(11), 1441–1451 (2013).
   PubMed Web of Science ®Google Scholar
• Honoki K, Yoshitani K, Tsujiuchi T et al. Growth inhibition and induction of apoptosis by flavopiridol in rat lung adenocarcinoma, osteosarcoma and malignant fibrous histiocytoma cell lines. Oncol. Rep. 11(5), 1025–1030 (2004).
   PubMedGoogle Scholar
• Morris DG, Bramwell VH, Turcotte R et al. A Phase II study of flavopiridol in patients with previously untreated advanced soft tissue sarcoma. Sarcoma 2006, 64374 (2006).
   PubMedGoogle Scholar
• Luke JJ, D’Adamo DR, Dickson MA et al. The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a Phase I dose-escalation clinical trial. Clin. Cancer Res. 18(9), 2638–2647 (2012).
   PubMed Web of Science ®Google Scholar
• Iurisci I, Filipski E, Reinhardt J et al. Improved tumor control through circadian clock induction by Seliciclib, a cyclin-dependent kinase inhibitor. Cancer Res. 66(22), 10720–10728 (2006).
   PubMed Web of Science ®Google Scholar
• Fu W, Ma L, Chu B et al. The cyclin-dependent kinase inhibitor SCH 727965 (dinacliclib) induces the apoptosis of osteosarcoma cells. Mol. Cancer Ther. 10(6), 1018–1027 (2011).
   PubMed Web of Science ®Google Scholar
• Cai Y, Mohseny AB, Karperien M et al. Inactive Wnt/beta-catenin pathway in conventional high-grade osteosarcoma. J. Pathol. 220(1), 24–33 (2010).
   PubMed Web of Science ®Google Scholar
• McQueen P, Ghaffar S, Guo Y, Rubin EM, Zi X, Hoang BH. The Wnt signaling pathway: implications for therapy in osteosarcoma. Expert Rev. Anticancer Ther. 11(8), 1223–1232 (2011).
   PubMed Web of Science ®Google Scholar
• Vijayakumar S, Liu G, Rus IA et al. High-frequency canonical Wnt activation in multiple sarcoma subtypes drives proliferation through a TCF/β-catenin target gene, CDC25A. Cancer Cell 19, 601–612 (2011).
   PubMedGoogle Scholar
• Adhikary S, Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat. Rev. Mol. Cell Biol. 6, 635–645 (2005).
   PubMed Web of Science ®Google Scholar
• Nie Z, Hu G, Wei G et al. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell 151, 68–79 (2012).
   PubMed Web of Science ®Google Scholar
• Lovén J, Orlando DA, Sigova AA et al. Revisiting global gene expression analysis. Cell 151, 476–482 (2012).
   PubMed Web of Science ®Google Scholar
• Wang H, Hammoudeh DI, Follis AV et al. Improved low molecular weight Myc-Max inhibitors. Mol. Cancer Ther. 6(9), 2399–2408 (2007).
   PubMed Web of Science ®Google Scholar
• Schwarze SR, Fu VX, Desotelle JA, Kenowski ML, Jarrard DF. The identification of senescence-specific genes during the induction of senescence in prostate cancer cells. Neoplasia 7(9), 816–823 (2005).
   PubMed Web of Science ®Google Scholar
• Ota H, Tokunaga E, Chang K et al. Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells. Oncogene 25(2), 176–185 (2006).
   PubMed Web of Science ®Google Scholar
• Filippakopoulos P, Qi J, Picaud S et al. Selective inhibition of BET bromodomains. Nature 468(7327), 1067–1073 (2010).
   PubMed Web of Science ®Google Scholar
• Delmore JE, Issa GC, Lemieux ME et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146(6), 904–917 (2011).
   PubMed Web of Science ®Google Scholar
• Harley CB. Telomerase and cancer therapeutics. Nat. Rev. Cancer 8, 167–179 (2008).
   PubMed Web of Science ®Google Scholar
• Fujimori J, Matsuo T, Shimose S et al. Antitumor effects of telomerase inhibitor TMPyP4 in osteosarcoma cell lines. J. Orthop. Res. 29(11), 1707–1711 (2011).
   PubMed Web of Science ®Google Scholar
• Parsch D, Brassat U, Brümmendorf TH, Fellenberg J. Consequences of telomerase inhibition by BIBR1532 on proliferation and chemosensitivity of chondrosarcoma cell lines. Cancer Invest. 26(6), 590–596 (2008).
   PubMed Web of Science ®Google Scholar
• Debacq-Chainiaux F, Erusalimsky JD, Campisi J, Toussaint O. Protocols to detect senescence-associated beta-galactosidase (SA-betagal) activity, a biomarker of senescent cells in culture and in vivo. Nat. Protoc. 4, 1798–1806 (2009).
   PubMed Web of Science ®Google Scholar
• Collado M, Gil J, Efeyan C et al. Tumour biology: senescence in premalignant tumours. Nature 436, 642 (2005).
   PubMed Web of Science ®Google Scholar
• Tung CH, Zeng Q, Shah Q et al. In vivo imaging of beta-galactosidase activity using far red fluorescent switch. Cancer Res. 64, 1579–1583 (2004).
   PubMed Web of Science ®Google Scholar
• Chang BD, Xuan Y, Broude EV et al. Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene 18(34), 4808–4818 (1999).
   PubMed Web of Science ®Google Scholar
• Schmitt CA, Friedman JS, Yang M et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 109(3), 335–346 (2002).
   PubMed Web of Science ®Google Scholar
• Beausejour CM, Krtolica A, Gamili F et al. Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J. 22(16), 4212–4222 (2003).
   PubMed Web of Science ®Google Scholar
• Trucco M, Loeb D. Sarcoma stem cells: do we know what we are looking for? Sarcoma 2012, e291705 (2012).
   PubMedGoogle Scholar
• Melo S, Villanueva A, Moutinho C et al. Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing. PNAS 108(11), 4394–4399 (2011).
   PubMed Web of Science ®Google Scholar